Following numerous neurodegenerative disease clinical failures, the neurodegenerative disease field requires a refreshed approach towards drug development to drive clinical success.
Now in its 7th year, the World CNS Summit challenges traditional thinking to guide drug development of efficacious treatments for neurodegeneration. Developed with experts from Eisai, Sanofi, Novartis and others, it is the only industry-specific conference focused on solving the translational challenges of neurodegenerative research.
Bringing together over 150+ leading minds in the neurodegenerative space, from academia, pharma, biotech and leading consortia, to provide a unique opportunity to bridge the gap of translational drug development.
- Network amongst a multidisciplinary mix of leading minds in the neurodegenerative space, from academia, pharma, biotech and leading consortia to challenge traditional thinking
- Learn about the latest developments, research and innovative technologies guiding future neurodegenerative research
- Collaborate with other leading pioneering companies to refresh and strengthen drug development of efficacious therapeutics